Many therapies are too fragile or too big to get into cells and are not easily targeted to specific sites of disease. To address these challenges, EvOx uses the body’s own natural delivery and messaging system: the exosome.
In March, EvOx Therapeutics signed a $44M licensing deal with Takeda. This was a landmark partnership for the company, positioning Evox at the forefront of a handful of players using exosomes to deliver therapeutic payloads to specific locations in the body. Read more about the deal here.
In June, Evox then announced a $1.2bn collaboration with Eli Lilly and Company to apply its exosome tech to neurological diseases. Read more about the deal here.